Robert C Olney1, Timothy C R Prickett, Eric A Espiner, William G Mackenzie, Angela L Duker, Colleen Ditro, Bernhard Zabel, Tomonobu Hasegawa, Hiroshi Kitoh, Arthur S Aylsworth, Michael B Bober. 1. Nemours Children's Clinic (R.C.O.), Jacksonville, Florida 32207; University of Otago (T.C.R.P., E.A.E.), Christchurch 8011, New Zealand; Nemours/Alfred I. duPont Hospital for Children (W.G.M., A.L.D., C.D., M.B.B.), Wilmington, Delaware 19803; University Hospital Freiburg (B.Z.), 79106 Freiburg, Germany; Keio University School of Medicine (T.H.), Tokyo 108-8345, Japan; Nagoya University School of Medicine (H.K.), Nagoya 464-8601, Japan; and University of North Carolina (A.S.A.), Chapel Hill, North Carolina 27599-2100.
Abstract
CONTEXT: C-type natriuretic peptide (CNP) is a crucial regulator of endochondral bone growth. In a previous report of a child with acromesomelic dysplasia, Maroteaux type (AMDM), caused by loss-of-function of the CNP receptor (natriuretic peptide receptor-B [NPR-B]), plasma levels of CNP were elevated. In vitro studies have shown that activation of the MAPK kinase (MEK)/ERK MAPK pathway causes functional inhibition of NPR-B. Achondroplasia, hypochondroplasia, and thanatophoric dysplasia are syndromes of short-limbed dwarfism caused by activating mutations of fibroblast growth factor receptor-3, which result in overactivation of the MEK/ERK MAPK pathway. OBJECTIVE: The purpose of this study was to determine whether these syndromes exhibit evidence of CNP resistance as reflected by increases in plasma CNP and its amino-terminal propeptide (NTproCNP). DESIGN: This was a prospective, observational study. SUBJECTS: Participants were 63 children and 20 adults with achondroplasia, 6 children with hypochondroplasia, 2 children with thanatophoric dysplasia, and 4 children and 1 adult with AMDM. RESULTS: Plasma levels of CNP and NTproCNP were higher in children with achondroplasia with CNP SD scores (SDSs) of 1.0 (0.3-1.4) (median [interquartile range]) and NTproCNP SDSs of 1.4 (0.4-1.8; P < .0005). NTproCNP levels correlated with height velocity. Levels were also elevated in adults with achondroplasia (CNP SDSs of 1.5 [0.7-2.1] and NTproCNP SDSs of 0.5 [0.1-1.0], P < .005). In children with hypochondroplasia, CNP SDSs were 1.3 (0.7-1.5) (P = .08) and NTproCNP SDSs were 1.9 (1.8-2.3) (P < .05). In children with AMDM, CNP SDSs were 1.6 (1.4-3.3) and NTproCNP SDSs were 4.2 (2.7-6.2) (P < .01). CONCLUSIONS: In these skeletal dysplasias, elevated plasma levels of proCNP products suggest the presence of tissue resistance to CNP.
CONTEXT: C-type natriuretic peptide (CNP) is a crucial regulator of endochondral bone growth. In a previous report of a child with acromesomelic dysplasia, Maroteaux type (AMDM), caused by loss-of-function of the CNP receptor (natriuretic peptide receptor-B [NPR-B]), plasma levels of CNP were elevated. In vitro studies have shown that activation of the MAPK kinase (MEK)/ERKMAPK pathway causes functional inhibition of NPR-B. Achondroplasia, hypochondroplasia, and thanatophoric dysplasia are syndromes of short-limbed dwarfism caused by activating mutations of fibroblast growth factor receptor-3, which result in overactivation of the MEK/ERKMAPK pathway. OBJECTIVE: The purpose of this study was to determine whether these syndromes exhibit evidence of CNP resistance as reflected by increases in plasma CNP and its amino-terminal propeptide (NTproCNP). DESIGN: This was a prospective, observational study. SUBJECTS:Participants were 63 children and 20 adults with achondroplasia, 6 children with hypochondroplasia, 2 children with thanatophoric dysplasia, and 4 children and 1 adult with AMDM. RESULTS: Plasma levels of CNP and NTproCNP were higher in children with achondroplasia with CNP SD scores (SDSs) of 1.0 (0.3-1.4) (median [interquartile range]) and NTproCNP SDSs of 1.4 (0.4-1.8; P < .0005). NTproCNP levels correlated with height velocity. Levels were also elevated in adults with achondroplasia (CNP SDSs of 1.5 [0.7-2.1] and NTproCNP SDSs of 0.5 [0.1-1.0], P < .005). In children with hypochondroplasia, CNP SDSs were 1.3 (0.7-1.5) (P = .08) and NTproCNP SDSs were 1.9 (1.8-2.3) (P < .05). In children with AMDM, CNP SDSs were 1.6 (1.4-3.3) and NTproCNP SDSs were 4.2 (2.7-6.2) (P < .01). CONCLUSIONS: In these skeletal dysplasias, elevated plasma levels of proCNP products suggest the presence of tissue resistance to CNP.
Authors: Eveline Boudin; Tjeerd R de Jong; Tim C R Prickett; Bruno Lapauw; Kaatje Toye; Viviane Van Hoof; Ilse Luyckx; Aline Verstraeten; Hugo S A Heymans; Eelco Dulfer; Lut Van Laer; Ian R Berry; Angus Dobbie; Ed Blair; Bart Loeys; Eric A Espiner; Jan M Wit; Wim Van Hul; Peter Houpt; Geert R Mortier Journal: Am J Hum Genet Date: 2018-07-19 Impact factor: 11.025
Authors: Jerid W Robinson; Jeremy R Egbert; Julia Davydova; Hannes Schmidt; Laurinda A Jaffe; Lincoln R Potter Journal: Cell Signal Date: 2017-09-28 Impact factor: 4.315
Authors: Brandon M Wagner; Jerid W Robinson; Yun-Wen Lin; Yi-Ching Lee; Nabil Kaci; Laurence Legeai-Mallet; Lincoln R Potter Journal: JCI Insight Date: 2021-05-10
Authors: Ricki S Carroll; Robert C Olney; Angela L Duker; Ryan F Coghlan; William G Mackenzie; Colleen P Ditro; Cassondra J Brown; David A O'Connell; William A Horton; Brian Johnstone; Eric A Espiner; Timothy C R Prickett; Michael B Bober Journal: Calcif Tissue Int Date: 2022-03-11 Impact factor: 4.000
Authors: Ricki S Carroll; Angela L Duker; Andrea J Schelhaas; Mary Ellen Little; Elissa G Miller; Michael B Bober Journal: Palliat Med Rep Date: 2020-05-14
Authors: Jerid W Robinson; Giulia Vigone; Leia C Shuhaibar; Ninna P Shuhaibar; Jeremy R Egbert; Valentina Baena; Tracy F Uliasz; Deborah Kaback; Siu-Pok Yee; Robert Feil; Melanie C Fisher; Caroline N Dealy; Lincoln R Potter; Laurinda A Jaffe Journal: Elife Date: 2017-12-04 Impact factor: 8.140